Ardelyx Advances IBSRELA into Phase 3 for Chronic Constipation

Event summary

  • Ardelyx dosed the first patient in the ACCEL Phase 3 trial for IBSRELA (tenapanor) in chronic idiopathic constipation (CIC).
  • The multicenter, randomized, double-blind, placebo-controlled study aims to enroll 700 patients, with topline data expected in late 2027.
  • IBSRELA is currently approved for irritable bowel syndrome with constipation (IBS-C) in adults.
  • CIC affects over 34 million Americans, representing a significant market opportunity.

The big picture

Ardelyx's Phase 3 trial for IBSRELA in CIC marks a strategic pivot to expand its product's reach beyond IBS-C. With CIC affecting a broader patient population, success could significantly boost Ardelyx's revenue and market position. The trial's outcome will be critical in determining whether tenapanor can become a leading therapy in gastrointestinal disorders.

What we're watching

Clinical Success
Whether IBSRELA demonstrates efficacy and safety in CIC, validating its expanded use beyond IBS-C.
Regulatory Pathway
The pace at which Ardelyx can secure approval for IBSRELA in CIC, given the Phase 3 data.
Market Penetration
How Ardelyx positions IBSRELA against existing CIC treatments, leveraging its differentiated mechanism of action.